
Biostate AI and Weill Cornell Medicine Develop AI for Leukemia Care
Biostate AI and Weill Cornell Medicine have announced a strategic collaboration to develop artificial intelligence models aimed at personalizing leukemia care, as stated in a press release. The partnership will initially focus on acute myeloid leukemia (AML), utilizing Weill Cornell's extensive biorepository of bone marrow and blood samples.
Biostate AI will employ its proprietary barcode-integrated reverse transcription (BIRT) technology for RNA sequencing to analyze RNA expression from patient samples. This data will be used to pre-train and fine-tune a transformer-based AI model, which will assist in AML subtype stratification, disease prognosis, and therapy selection.
The collaboration will begin with a pilot phase involving 1,000 retrospective samples, with plans to expand to 50,000 samples upon achieving certain technical milestones. This effort aims to enhance the precision of treatment decisions, potentially improving patient outcomes by tailoring therapies such as bone marrow transplants and BCL-2 inhibitors.
We hope you enjoyed this article.
Consider subscribing to one of several newsletters we publish like Life AI Weekly.
Also, consider following us on social media:
More from: Healthcare & Life Sciences
Invetech and AiCella Collaborate to Enhance Cell Therapy with AI
Core Solutions and OPEN MINDS Launch AI Advisory Board for Behavioral Health
Avio Health Unveils Functional Medicine LLM for Personalized Healthcare
Novo Nordisk Foundation Allocates DKK 479 Million for AI and Health Projects
Subscribe to Life AI Weekly
Weekly coverage of AI applications in healthcare, drug development, biotechnology research, and genomics breakthroughs.
Market report
AI’s Time-to-Market Quagmire: Why Enterprises Struggle to Scale AI Innovation
The 2025 AI Governance Benchmark Report by ModelOp provides insights from 100 senior AI and data leaders across various industries, highlighting the challenges enterprises face in scaling AI initiatives. The report emphasizes the importance of AI governance and automation in overcoming fragmented systems and inconsistent practices, showcasing how early adoption correlates with faster deployment and stronger ROI.
Read more